Skip to content

Application of sub-anaesthetic dose of s-ketamine in controlled low central venous pressure hepatectomy

Application of sub-anaesthetic dose of s-ketamine in controlled low central venous pressure hepatectomy

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000037747
Enrollment
Unknown
Registered
2020-08-31
Start date
2020-09-07
Completion date
Unknown
Last updated
2020-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver disease

Interventions

Experimental group:0.5 mg/kg s ketamine before operation, 0.3 mg/kg/h ketamine was continuously pumped during the operation to 30 minutes before the end of the operation

Sponsors

Hu'nan Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18-60 years had ASA grade I-II and child Pugh Grade A; 2. For patients who are scheduled for hepatectomy, the porta hepatis should be blocked during the operation, and the range of hepatectomy should be at least two segments; 3. Patients who voluntarily sign ethical informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with a history of hepatectomy; 2. Patients with massive intraoperative bleeding (total bleeding volume >= 1000ml or bleeding volume within 2min >= 400ml); The patient has difficulty in communication; 4. Patients with a history of serious cardiovascular and cerebrovascular diseases; 5. Patients with other organ dysfunction; 6. Pregnant women and patients in lactation period; 7. Patients with emergency operation; 8. In patients with arrhythmia during operation, non sinus rhythm was more than 4 times / min, lasting for more than 5 minutes; 9. Patients with endocrine diseases, chronic lung diseases and immunosuppressants; 10. Patients with a long history of taking analgesics and sedatives, taking drugs and being allergic to narcotic drugs; 11. Patients with abnormal coagulation function.

Design outcomes

Primary

MeasureTime frame
MAP;HR;recovery time;Ramsay score;VAS score;Tumor Necrosis Factor-alpha;Interleukin-6;Interleukin-10;TOA;TAC;PON-1;

Countries

China

Contacts

Public ContactYuan Zhao

Hu'nan Provincial People's Hospital

no861@163.com+86 13755106141

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026